Tagged: , ,

Viewing 0 reply threads
  • Author
    • #21806
      John Connor

      As usual, this story would be years off and hasn’t even been peer-reviewed yet. I’m reporting it cos I’ve spent 2 hours researching it – so there.

      There’s been oodles of science re EBCV & MS – we currently carry 82 stories about this on our home site.

      ‘A phase 1 clinical trial by the California-based immunotherapy company Atara Biotherapeutics confirms latent Epstein-Barr (EBV) infections are viable targets for treating MS in at least some patients, reinforcing a curious link between the virus and a deadly illness that affects millions around the world.

      Out of the trial’s 24 volunteers, 20 showed signs of either improvement or at least a halt in their health’s steady decline. Importantly, there were no signs of serious side effects.

      Any thoughts on this study?

Viewing 0 reply threads
  • You must be logged in to reply to this topic.

©2022 KLEO Template a premium and multipurpose theme from Seventh Queen


We're not around right now. But you can send us an email and we'll get back to you, asap.


Log in with your credentials


Forgot your details?

Create Account